Mordechai R Kramer1, Yael Refaely2, Nimrod Maimon3, Dror Rosengarten4, Oren Fruchter4. 1. Pulmonary Institute Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. Electronic address: kramerm@netvision.net.il. 2. Department of Thoracic Surgery, Soroka Medical Center, Be'er Sheeva, Israel. 3. Department of Pulmonary Medicine, Soroka Medical Center, Be'er Sheeva, Israel. 4. Pulmonary Institute Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Abstract
BACKGROUND: A clinical study was performed to assess the safety and efficacy of bilateral AeriSeal Emphysematous Lung Sealant System (ELS) treatment in patients with advanced emphysema out to 1 year. METHODS: Twenty patients received treatment at four subsegments, two in each upper lobe. Tenhad upper lobe disease, and 10 had homogeneous disease. Treatments were administered under moderate sedation. Efficacy was assessed at 3, 6, and 12 months. RESULTS: Procedure times were short (15.2 ± 9.6 min), and hospital length of stay averaged 1.1 days. The study was successful in reaching its primary end point of a reduction at 3 months in upper lobe lung volume assessed by quantitative CT scan analysis ( - 895 ± 484 mL, P < .001). Treatment was associated with improvements in spirometry ( Δ FEV 1 at 6 months = 31.2% ± 36.6%, 12 months = 25.0% ± 33.4%), gas trapping ( Δ residual volume/total lung capacity at 6 months = 2 7.2% 12.7%, 12 months = - 10.9% 14.0%), diffusing capacity of lung for carbonmonoxide (6 months = 12.7% ± 16.4%, 12 months = 12.3% ± 21.1%), symptom scores ( Δ Medical Research Council dyspnea score at 6 months = median 0, range - 2 to 1, 12 months = median - 1, range - 3 to 0), and health-related quality of life ( Δ St. George Respiratory Questionnaire at 6 months = 8.0 ± 17.2 U, 12 months = 7.0 ± 15.8 U). There was one serious procedural complication and seven all-cause significant respiratory adverse events over 17 patient-years of follow-up. CONCLUSIONS: Bilateral ELS treatment administered under conscious sedation in patients with advanced emphysema is associated with short procedure time and length of hospital stay and produces physiologic and functional improvement out to 1 year.
BACKGROUND: A clinical study was performed to assess the safety and efficacy of bilateral AeriSeal Emphysematous Lung Sealant System (ELS) treatment in patients with advanced emphysema out to 1 year. METHODS: Twenty patients received treatment at four subsegments, two in each upper lobe. Tenhad upper lobe disease, and 10 had homogeneous disease. Treatments were administered under moderate sedation. Efficacy was assessed at 3, 6, and 12 months. RESULTS: Procedure times were short (15.2 ± 9.6 min), and hospital length of stay averaged 1.1 days. The study was successful in reaching its primary end point of a reduction at 3 months in upper lobe lung volume assessed by quantitative CT scan analysis ( - 895 ± 484 mL, P < .001). Treatment was associated with improvements in spirometry ( Δ FEV 1 at 6 months = 31.2% ± 36.6%, 12 months = 25.0% ± 33.4%), gas trapping ( Δ residual volume/total lung capacity at 6 months = 2 7.2% 12.7%, 12 months = - 10.9% 14.0%), diffusing capacity of lung for carbonmonoxide (6 months = 12.7% ± 16.4%, 12 months = 12.3% ± 21.1%), symptom scores ( Δ Medical Research Council dyspnea score at 6 months = median 0, range - 2 to 1, 12 months = median - 1, range - 3 to 0), and health-related quality of life ( Δ St. George Respiratory Questionnaire at 6 months = 8.0 ± 17.2 U, 12 months = 7.0 ± 15.8 U). There was one serious procedural complication and seven all-cause significant respiratory adverse events over 17 patient-years of follow-up. CONCLUSIONS: Bilateral ELS treatment administered under conscious sedation in patients with advanced emphysema is associated with short procedure time and length of hospital stay and produces physiologic and functional improvement out to 1 year.
Authors: Carolyn E Come; Mordechai R Kramer; Mark T Dransfield; Muhanned Abu-Hijleh; David Berkowitz; Michela Bezzi; Surya P Bhatt; Michael B Boyd; Enrique Cases; Alexander C Chen; Christopher B Cooper; Javier Flandes; Thomas Gildea; Mark Gotfried; D Kyle Hogarth; Kumaran Kolandaivelu; William Leeds; Timothy Liesching; Nathaniel Marchetti; Charles Marquette; Richard A Mularski; Victor M Pinto-Plata; Michael A Pritchett; Samaan Rafeq; Edmundo R Rubio; Dirk-Jan Slebos; Grigoris Stratakos; Alexander Sy; Larry W Tsai; Momen Wahidi; John Walsh; J Michael Wells; Patrick E Whitten; Roger Yusen; Javier J Zulueta; Gerard J Criner; George R Washko Journal: Eur Respir J Date: 2015-04-02 Impact factor: 16.671
Authors: Farbod N Rahaghi; Carolyn E Come; James Ross; Rola Harmouche; Alejandro A Diaz; Raul San Jose Estepar; George Washko Journal: Chronic Obstr Pulm Dis Date: 2015
Authors: Zaid Zoumot; Samuel V Kemp; Suveer Singh; Stephen R Bicknell; William H McNulty; Nicholas S Hopkinson; Ewen T Ross; Pallav L Shah Journal: PLoS One Date: 2015-04-08 Impact factor: 3.240
Authors: Mostafa Bakeer; Taha Taha Abdelgawad; Raed El-Metwaly; Ahmed El-Morsi; Mohammad Khairy El-Badrawy; Solafa El-Sharawy Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-08-03